A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297 · MANGROVE Phase 3Active, not recruiting
- Lead sponsor
- BeOne Medicines (Industry)
- Enrollment
- 510 (actual)
- Start date
- 20 Aug 2019
- Primary completion
- 27 Apr 2026 (actual)
- Study completion
- 30 Sep 2031
- Last update posted
- 30 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- zanubrutinib Drug
- bendamustine Drug
- rituximab Drug
Conditions and primary outcome
- Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Primary outcome
Progression-free survival (PFS) determined by independent central review (Up to approximately 7 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedA Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Future oncology (London, England) · 2021 Jan
PubMed 32985902 (opens in a new tab)DOI 10.2217/fon-2020-0794 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04002297 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.